News

For BRCA1/2 and other genes, it is important that practitioners begin testing for heriditary genes for ovarian cancers.

The UK Myeloma Forum and the British Society for Haematology collaborated to create a comprehensive, multidisciplinary guideline document for the screening, management, and long-term care of patients with myeloma.

The Paxman Scalp Cooling System has been granted FDA clearance to reduce hait loss in patients with breast cancer recieving chemotherapy.

New modalities of treatments for patients with Ewing sarcoma have expanded overall survival. However, there are few studies done on the long-term quality of life issues these patients may experience.

Several patient-related risk factors for chemotherapy-induced nausea and vomiting (CINV) have been identified and compiled into a CINV prediction tool.

With more patients diagnosed with breast cancer looking to contralateral prophylactic mastectomy, it is important that surgeons discuss this procedure in-depth so patients can better understand.

The Food and Drug Administration (FDA) granted an accelerated approval to atezolizumab (Tecentriq) to be used as a frontline treatment for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma (mUC).

The FDA has eliminated the need for REMS certification before administration of ESAs for anemia due to myelosuppressive chemotherapy.

Amanda Bontempo, MS, RD, CSO, CDN, gives some tips for healthy eating. Join us on 4/18 at 1 PM for our tweetchat, with Bontempo as moderator, to discuss more nutrition.

After losing her husband to stage III esophageal cancer, Mindy Mordecai came together with top physicians, business leaders and families affected by the disease to found Esophageal Cancer Action Network (ECAN).

There may be a shift away from the USPSTF's opposition to routine PSA screening for prostate cancer in some men.

A recent study determined that an education initiative could help to ease worries patients with cancer may have about palliative care, thus improving quality of life.

As prevalence of HPV within the population rises, incidence of HPV-related cancers is expected to rise.

For adolescent and young adult patients with cancer, navigating social life after their diagnosis can be difficult.

A recent review has found substantial evidence linking androgen deprivation therapy (ADT) to dementia in patients with prostate cancer.

Tricia Strusowski, MS, RN, discusses the importance of a nurse navigator to both the patient and the center.

With antiretroviral drugs easing the burden of AIDS-defining cancers in HIV-positive patients, the most common cancers in this population are expected to shift to those associated with aging.

A new policy statement from ASCO addresses the specific needs in oncology of patients in the sexual and gender minority populations.

A recent meta-analysis found that the most effective treatments for cancer-related fatigue are exercise and psychological interventions.

People with certain disabilities were found to be less likely to follow recommended guidelines for colorectal cancer screening.

Sixteen percent of patients with metastatic non-small cell lung cancer (NSCLC) receiving nivolumab survived after 5 years.

A shorter length of sleep may lead to an increased risk of death from prostate cancer, according to a recent study presented at the 2017 AACR Annual Meeting.

According to findings presented at the 2017 AACR Annual Meeting, aspirin use was associated with lower mortality in colorectal cancer.

Fewer people are dying from cancer than years ago, according to a recent study.

For patients with glioblastoma multiforme (GBM), tumor treating fields (TTFields) reduced the risk of death by 37% and extended overall survival by a median of 5 months.

For patients with cancer, smoking cessation should include counseling and pharmacology. Encouragement throughout, especially if a patient relapses is important.

A recent study found that individuals who had the chickenpox virus when they were younger were less likely to eventually develop gliomas.

Subcutaneous co-formulation of rituximab for treatment of patients with certain types of lymphoma and leukemia advances toward approval.